Common use of Commission-based Solicitors Clause in Contracts

Commission-based Solicitors. You are not aware of any person or entity, other than any person or entity engaged directly by the issuer, entitled (directly or indirectly) to receive any remuneration in connection with this offering other than as identified by you in writing to the issuer’s outside corporate counsel within the 20 days prior to the consummation of the offering. ZIOPHARM ONCOLOGY, INC. CONFIDENTIAL Rule 506 Disqualification Event Questionnaire (“Entity”) COMPLETED ON BEHALF OF: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, On behalf of The University of Texas M.D. Xxxxxxxx Cancer Center This questionnaire is being furnished to you to obtain information in connection with a potential offering (the “Offering”) of securities under Rule 506 of the Securities Act of 1933 (the “Securities Act”). As used in this questionnaire, “you” refers to any entity on whose behalf you are responding. Please review Exhibit A and confirm that you can make all of the statements on behalf of Entity. If you cannot make one or more of the statements, please contact us to provide details. If you have doubts regarding whether you can make all of the statements, please contact us. By completing and signing this questionnaire, you also indicate that: (i) Xxxxxx LLP and its clients may rely upon the information provided; (ii) you will notify Xxxxxx LLP and the Issuer of securities of any changes in information provided that occurs after the date you sign the questionnaire and prior to the applicable offering of securities; and (iii) the statements on Exhibit A are true and correct, to the best of your knowledge and belief after a reasonable investigation, as of the date you sign the questionnaire. Please return this Questionnaire to Xxxxxx LLP, Attn: Xxxxxxxxxxx Xxxxx, by e-mail to xxxxxx@xxxxxx.xxx. If you have any questions with respect to these matters, please contact Xxxxx at xxxxxx@xxxxxx.xxx or 000-000-0000. The statements on Exhibit A are true and correct to the best of my knowledge, information and belief after a reasonable investigation as of the date below.

Commission-based Solicitors. You are not aware of any person or entity, other than any person or entity engaged directly by the issuer, entitled (directly or indirectly) to receive any remuneration in connection with this offering other than as identified by you in writing to the issuer’s outside corporate counsel within the 20 days prior to the consummation of the offering. ZIOPHARM ONCOLOGY, INC. CONFIDENTIAL Rule 506 Disqualification Event Questionnaire (“Entity”) COMPLETED ON BEHALF OF: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, On behalf of The University of Texas M.D. Xxxxxxxx Cancer Center INTREXON CORPORATION This questionnaire is being furnished to you to obtain information in connection with a potential offering (the “Offering”) of securities under Rule 506 of the Securities Act of 1933 (the “Securities Act”). As used in this questionnaire, “you” refers to any entity on whose behalf you are responding. Please review Exhibit A and confirm that you can make all of the statements on behalf of Entity. If you cannot make one or more of the statements, please contact us to provide details. If you have doubts regarding whether you can make all of the statements, please contact us. By completing and signing this questionnaire, you also indicate that: (i) Xxxxxx LLP and its clients may rely upon the information provided; (ii) you will notify Xxxxxx LLP and the Issuer of securities of any changes in information provided that occurs after the date you sign the questionnaire and prior to the applicable offering of securities; and (iii) the statements on Exhibit A are true and correct, to the best of your knowledge and belief after a reasonable investigation, as of the date you sign the questionnaire. Please return this Questionnaire to Xxxxxx LLP, Attn: Xxxxxxxxxxx Xxxxx, by e-mail to xxxxxx@xxxxxx.xxx. If you have any questions with respect to these matters, please contact Xxxxx at xxxxxx@xxxxxx.xxx or 000-000-0000. The statements on Exhibit A are true and correct to the best of my knowledge, information and belief after a reasonable investigation as of the date below.. INTREXON CORPORATION By: Name: Title: Date: Exhibit A

Commission-based Solicitors. You are not aware of any person or entity, other than any person or entity engaged directly by the issuer, entitled (directly or indirectly) to receive any remuneration in connection with this offering other than as identified by you in writing to the issuer’s outside corporate counsel within the 20 days prior to the consummation of the offering. ZIOPHARM ONCOLOGY, INC. INTREXON CORPORATION CONFIDENTIAL Rule 506 Disqualification Event Questionnaire (“Entity”) COMPLETED ON BEHALF OF: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, On behalf of The University of Texas M.D. Xxxxxxxx Cancer Center This questionnaire is being furnished to you to obtain information in connection with a potential offering (the “Offering”) of securities under Rule 506 of the Securities Act of 1933 (the “Securities Act”). As used in this questionnaire, “you” refers to any entity on whose behalf you are responding. Please review Exhibit A and confirm that you can make all of the statements on behalf of Entity. If you cannot make one or more of the statements, please contact us to provide details. If you have doubts regarding whether you can make all of the statements, please contact us. By completing and signing this questionnaire, you also indicate that: (i) Xxxxxx LLP and its clients may rely upon the information provided; (ii) you will notify Xxxxxx LLP and the Issuer of securities of any changes in information provided that occurs after the date you sign the questionnaire and prior to the applicable offering of securities; and (iii) the statements on Exhibit A are true and correct, to the best of your knowledge and belief after a reasonable investigation, as of the date you sign the questionnaire. Please return this Questionnaire to Xxxxxx LLP, Attn: Xxxxxxxxxxx Xxxxx, by e-mail to xxxxxx@xxxxxx.xxx. If you have any questions with respect to these matters, please contact Xxxxx at xxxxxx@xxxxxx.xxx or 000-000-0000. The statements on Exhibit A are true and correct to the best of my knowledge, information and belief after a reasonable investigation as of the date below.